MMV

MMV is recognized as the leading product development partnership (PDP) in the field of antimalarial drug research and development.

The Centre has partnered with MMV as a Product Development Partnership. The Australian Government’s partnership with MMV began in 2015, with the PDP receiving $10 million over three years to 2018. In 2017 an independent review found that DFAT’s investment in PDPs, through core funding, represented good value for money and that MMV’s innovations had made significant contributions to malaria elimination globally and in Australia’s region.

Following the recommendations of the 2017 review, the Health Security Initiative invested an additional $18.5 million in MMV under the $75 million Product Development Partnership Fund.

Although a small organisation, MMV has a broad reach internationally, both in the Asia Pacific region and elsewhere. Australia’s continued and visible support of MMV demonstrates the reach, the concern and the engagement of the country in combatting a disease of world-wide concern.

KEY INVESTMENT OUTCOME

Pyramax®

This is the first ACT to be granted positive scientific opinion under EMA Article 58 procedure, including the first approval for paediatric use (2015 – including approval for paediatric granules and a newly expanded label for adult tablets). The product is the first and only ACT approved for blood-stage treatment of P. falciparum and P. vivax, and will make a significant impact on the treatment of malaria in children.